Canada markets close in 2 hours 17 minutes

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.8868-0.1232 (-6.13%)
As of 01:41PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close2.0100
Bid1.9000 x 2900
Ask1.9000 x 1300
Day's Range1.8700 - 2.0200
52 Week Range1.0250 - 2.3900
Avg. Volume1,364,006
Market Cap313.228M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)-0.4300
Earnings DateMar 19, 2024 - Mar 26, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.62
  • GlobeNewswire

    atai Life Sciences Appoints Anne Johnson as Chief Financial Officer

    NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO). Anne succeeds Stephen Bardin as the Company’s CFO while Stephen will continue in an advisory role until March 31, 2024 to support the transition. “Anne has been an integral member of our team for

  • Market Exclusive

    Weekly Roundup on the Cannabis Sector & Psychedelic Sector

    Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector This week was the inaugural week of 2024, a year poised to be a dynamic rollercoaster of highs and lows in the ever-evolving landscape of the cannabis and psychedelic sectors. As we step into the unknown, anticipation runs high, especially in the cannabis sector, where investors eagerly […]

  • GlobeNewswire

    atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics

    Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidatesTwo patent-protected, clinical-stage programs BPL-003 (intranasal 5-MeO-DMT) and ELE-101 (intravenous psilocin) complement atai’s existing drug development programs Multiple clinical readouts anticipated from this investment in Beckley Psytech within next 12 months, including a Phase 2b readout of BPL-003 in Treatm